I think some here and on the other boards are focu
Post# of 9122
Money, time and other resources has been spent to develop the N-Assay for Group B Strep and a couple others that were talked about in Dr. Sebastian Faro's presentation. I am anxiously waiting for publication of the study as it is the next logical step toward commercial launch. We know that the Company has limited financial resources and I would be disappointed if the Company split its focus to aggressively pursue N-Assay (V). I don't believe this is the case since the Company did announce that they are looking for a Corporate partner.
I hope that a partner steps up, but the Company should have gotten all the recent attention and more from its development of the N-Assay, BNP and Flatpack technologies. We've become an ebola play due to current events and that is great! But as I said, the biggest benefit to the Company and to investors is the exposure that the Company has gotten to a much larger investor pool.